Dermapharm Holding Se · XETR:DMP

Dermapharm — Q1 2021 Earnings Presentation

17 slides from Dermapharm's earnings presentation, May 18, 2021

  1. Slide 1: Investors' and Analysts' Conference Call Q1 2021

    INVESTORS’ AND ANALYSTS’ CONFERENCE CALL Q1 2021 Grünwald, 18 May 2021

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta

  3. Slide 3: Agenda

    AGENDA 1. Highlights Q1 2021 2. Financial figures Q1 2021 3. Outlook FY 2021 4. Q & A

  4. Slide 4: Agenda: Highlights Q1 2021

    AGENDA 1. Highlights Q1 2021 2. Financial figures Q1 2021 3. Outlook FY 2021 4. Q & A

  5. Slide 5: Highlights Q1 2021

    Highlights Q1 2021 Dermapharm with accelerated growth in first quarter COVID-19 pandemic Despite ongoing lockdown measures successful continuation of growth path – solid basis for further growth of current business year Allergopharma Integration into Dermapharm Group completed – measures to optimise

  6. Slide 6: Agenda: Financial figures Q1 2021

    AGENDA 1. Highlights Q1 2021 2. Financial figures Q1 2021 3. Outlook FY 2021 4. Q & A

  7. Slide 7: Dermapharm Group: Strong growth during COVID-19 pandemic

    Dermapharm Group Strong growth during COVID-19 pandemic Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA margin +10.2% YoY 25.7% 30.0% Significant revenue growth of 10.2% to €212.2m, due to 212.2  revenue contribution of acquisition Allergopharma, not considered in Q1 2020 192.5  organi

  8. Slide 8: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Growth expansion driven by integration of Allergopharma Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +22.7% YoY 41.1% 45.1% Revenues up by 22.7% to €130.3m  mainly based on contribution of Allergopharma  growth in vitamins / min

  9. Slide 9: Herbal extracts: Recovery after COVID-19 pandemic

    Herbal extracts Recovery after COVID-19 pandemic Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin 5.8% YoY 20.6% 27.5% Revenues increased by 5.8% to €20.0m, comprising Euromed  recovering global demand for herbal extracts  growing market activities in America and Asia EBITDA increased

  10. Slide 10: Parallel import business

    Parallel import business Despite higher sales in narcotics and medical cannabis, decrease in PI Revenue (€m) EBITDA (€m) Comments EBITDA Margin -8.3% YoY 4.4% 1.6% Revenues decreased by 8.3% to €61.9m  the demand in the entire market is still affected by the COVID-19 pandemic  increasing demand fo

  11. Slide 11: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increased due to M&A and business growth Earnings before tax (EBT)(1) (€m) Comments EBT Margin 19.1% 23.1%  EBT increased by 33.2% to €49.0m (unadjusted) resulting in a margin of 23.1% Mainly influenced by +33.2% YoY  disproportional increase of depreciation

  12. Slide 12: Strong operating cash flows and cash conversion

    Strong operating cash flows and cash conversion Dedication to future growth Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 60.7% 59.3%  CF from operating activities increased, mainly influenced  by increased EBT in 3M 2021  and by increased tax payments  CF fr

  13. Slide 13: Balance sheet of Dermapharm Group

    Balance sheet of Dermapharm Group Balance Sheet as of 31 March 2021 (€m) Comments  Total assets increased to €1,277m (31 December 2020: €1,224m) 1,277 1,277  Non-current assets on the same level at €823m (31 December 2020: €824m)  Current assets increased to €454m (31 December 2020: €400m), mainl

  14. Slide 14: Agenda: Outlook FY 2021

    AGENDA 1. Highlights Q1 2021 2. Financial figures Q1 2021 3. Outlook FY 2021 4. Q & A

  15. Slide 15: Outlook 2021: Growth strategy on track, confirming guidance

    Outlook 2021 Growth strategy on track – confirming guidance 2021 positive growth of 24 - 26% Revenues 2021 vs. previous year (€793.8m) EBITDA 2021 positive growth of 45 - 50% (adjusted) vs. previous year (€200.7m) Growth rates are based on organic growth supported by new launches of in-house develop

  16. Slide 16: Agenda: Q & A

    AGENDA 1. Highlights Q1 2021 2. Financial figures Q1 2021 3. Outlook FY 2021 4. Q & A

  17. Slide 17: For information, please contact

    For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

Dermapharm Holding — Q1 2021 Earnings Presentation on 6ix